tRF-Val-TAC-022在肺癌淋巴结转移诊断中的应用
By detecting the expression level of the biomarker tRF-Val-TAC-022, the challenge of early diagnosis of lymph node metastasis in lung cancer has been solved, enabling rapid and accurate diagnosis and improving the selectivity of treatment options.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- JIANGSU CANCER HOSPITAL
- Filing Date
- 2025-06-25
- Publication Date
- 2026-07-17
AI Technical Summary
Current technology lacks specific methods for early diagnosis of lymph node metastasis in lung cancer, resulting in some patients developing lymph node metastasis when the tumor is still small, making it impossible to adjust the surgical approach in advance and affecting the treatment outcome.
Using the biomarker tRF-Val-TAC-022, we detected its expression level in the serum of lung cancer patients. Its significantly high expression in patients with positive lymph node metastasis was used as a biomarker for early diagnosis of lung cancer lymph node metastasis, providing a rapid and accurate diagnostic method.
It enables early and rapid diagnosis of lymph node metastasis in lung cancer, improving diagnostic accuracy and sensitivity, and helping clinicians select appropriate treatment options.
Smart Images
Figure CN120591405B_ABST